Research & Interest

Dr. Mitsuyasu is Professor of Medicine and the Director of the UCLA Center for Clinical AIDS Research and Education (CARE Center). Dr Mitsuyasu is the Associate Director of the UCLA AIDS Institute responsible for overseeing the clinical therapeutic and biomedical prevention areas. He is an established clinical investigator with over 23 years of experience in HIV clinical trials research and patient care. He established one of the first clinics for Kaposi’s sarcoma and AIDS malignancies at UCLA in 1983 and has directed the CARE Center and Clinic since its inception in 1990. He is the current group chair of the NCI-funded AIDS Malignancy Consortium (AMC) and is director of the Universitywide AIDS Research Program (UARP)-supported UCLA Collaborative Center for HIV/AIDS Research in California, which is known as the Network for AIDS Research in Los Angeles (NARLA). This later organization is a consortium of UCLA with 3 other LA based community service and research organizations: AIDS Project Los Angeles, Friends Research Institute, Inc and T.H.E. (To-help-everyone) Clinic. He has served as chair of the Immunology Research Agenda Committee in the NIAID-funded Adult AIDS Clinical Trials Group (AACTG). Dr. Mitsuyasu’s research interests include clinical trial investigations of cytokines, immune-based therapies, biologic response modifiers, vaccines and gene therapies for HIV and treatments for AIDS-related malignancies.

Selected Publications

• Martin BK, Wu  AW, Gelman R, Mitsuyasu RT. Quality of Life in a Clinical Trial of Highly Active Antiretroviral Therapy Alone or With Intravenous or Subcutaneous Interleukin-2 Administration. AIDS 40:428-433, 2005.

• Kuekrek H, Schlingmann T, Valdez H, Boehm BO, Pollard RB, Mitsuyasu R, Goebel FD, Lederman MM, Lehmann PV, Tary-Lehmann M. Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS. 19(17): 1967-1974 2005.

• Kilby JM, Bucy RP, Mildvan D, Fischl M, Santa-Bagur J, Lennox J, Pilcher C, Zolopa A. Lswrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R: Adult AIDS Clinical Trials Group A5024 Protocol Team. A randomized, partially-blinded phase II trial of antiretroviral therapy, HIV-specific immunization and Interleukin-2 cylces to promote efficient control of viral replication (ACTG A5024). J Infect Dis. 194(12):1672-6, 2006.

• Mitsuyasu R, Gelman R, Cherng D, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege A-M, Pollard RB for the ACTG 328 Study Team.  The virologic, immunologic and clinical effects of interleukin-2 with potent antiretroviral therapy in patients with moderately advanced HIV infection. Arch Intern Med 167;597-605, 2007.

• Anton PA, Mitsuyasu RT, Deeks, SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C,  Borellini F, Lazar R, Hege KM.  Multiple measure of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects.  AIDS 17:53-63, 2003.

• de Boer AW, Markowitz N, Lane CH, Saravolatz LD, Koletar S, Donabedian H, Yoshizawa C, Duliege A-M, Fyfe G, Mitsuyasu RT. A randomized controlled trial evaluating the efficacy and safety of intermittent continuous intravenous recombinant Interleukin-2 for 3, 4 and 5 days combined with antiretroviral therapy (ART vs ART alone in HIV-seropositive patients with 100-300 CD4 T-cells/mm3.  Clin Immunol 106:188-196, 2003.

• Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Boyd MP, MacPherson JL, Fanning GC, Todd AV, Ely JA, Zack JA, Symonds GP.  Anti-HIV hematopoietic progenitor cell-delivered reiboxyme in a phase I study: myeloid and lymphoid reconstitution in HIV-1-infected patients.  Hum Gene Ther  15(3):251-62, 2004.